NBIX vs. ABT
NBIX (Neurocrine Biosciences, Inc.) and ABT (Abbott Laboratories) are both stocks. Both are in the Healthcare sector — NBIX in Drug Manufacturers - Specialty & Generic, ABT in Medical Devices. Over the past 10 years, NBIX returned 12.80%/yr vs 10.35%/yr for ABT. At a 0.22 correlation, their price movements are largely independent.
Performance
NBIX vs. ABT - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBIX achieves a 16.41% return, which is significantly higher than ABT's -29.78% return. Over the past 10 years, NBIX has outperformed ABT with an annualized return of 12.80%, while ABT has yielded a comparatively lower 10.35% annualized return.
NBIX
- 1D
- 6.63%
- 1M
- 23.15%
- YTD
- 16.41%
- 6M
- 8.65%
- 1Y
- 32.09%
- 3Y*
- 21.38%
- 5Y*
- 11.83%
- 10Y*
- 12.80%
ABT
- 1D
- 0.02%
- 1M
- -0.63%
- YTD
- -29.78%
- 6M
- -29.78%
- 1Y
- -33.61%
- 3Y*
- -3.93%
- 5Y*
- -2.65%
- 10Y*
- 10.35%
NBIX vs. ABT - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 16.41% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
ABT Abbott Laboratories | -29.78% | 12.87% | 4.81% | 2.26% | -20.68% | 30.53% | 28.04% | 22.08% | 29.06% | 52.03% |
Correlation
The correlation between NBIX and ABT is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.15 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.16 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.21 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since May 24, 1996 | 0.22 |
The correlation between NBIX and ABT shifts across timeframes, from 0.15 (1 year) to 0.27 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
NBIX:
$17.07B
ABT:
$151.97B
NBIX:
$6.53
ABT:
$3.59
NBIX:
25.28
ABT:
24.24
NBIX:
0.50
ABT:
1.51
NBIX:
5.45
ABT:
3.37
NBIX:
5.01
ABT:
2.30
NBIX:
$3.10B
ABT:
$45.13B
NBIX:
$3.05B
ABT:
$25.45B
NBIX:
$881.20M
ABT:
$10.80B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. ABT — Risk / Return Rank
NBIX
ABT
NBIX vs. ABT - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Abbott Laboratories (ABT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| NBIX | ABT | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.44 | ||
| Sortino ratioReturn per unit of downside risk | +3.46 | ||
| Omega ratioGain probability vs. loss probability | 1.21 | 0.74 | +0.47 |
| Calmar ratioReturn relative to maximum drawdown | 1.54 | -0.86 | +2.41 |
| Martin ratioReturn relative to average drawdown | 3.39 | -2.00 | +5.39 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| NBIX | ABT | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.04 | -1.41 | +2.44 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.36 | -0.12 | +0.48 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.33 | 0.44 | -0.11 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.15 | 0.49 | -0.34 |
Drawdowns
NBIX vs. ABT - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than ABT's maximum drawdown of -45.66%. Use the drawdown chart below to compare losses from any high point for NBIX and ABT.
Loading charts...
Drawdown Indicators
| NBIX | ABT | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -45.66% | -51.55% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -38.99% | +18.09% |
Max Drawdown (3Y)Largest decline over 3 years | -42.89% | -39.64% | -3.25% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -39.64% | -3.25% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | -39.64% | -6.75% |
Current DrawdownCurrent decline from peak | 0.00% | -36.40% | +36.40% |
Average DrawdownAverage peak-to-trough decline | -43.85% | -10.83% | -33.02% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.48% | 16.86% | -7.38% |
Volatility
NBIX vs. ABT - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 12.60% compared to Abbott Laboratories (ABT) at 7.34%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than ABT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBIX | ABT | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.60% | 7.34% | +5.26% |
Volatility (6M)Calculated over the trailing 6-month period | 23.57% | 18.93% | +4.64% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.08% | 23.96% | +7.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.72% | 21.97% | +10.75% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.19% | 23.63% | +15.56% |
Dividends
NBIX vs. ABT - Dividend Comparison
NBIX has not paid dividends to shareholders, while ABT's dividend yield for the trailing twelve months is around 2.80%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABT Abbott Laboratories | 2.80% | 1.88% | 1.95% | 1.85% | 1.71% | 1.28% | 1.32% | 1.47% | 1.55% | 1.86% | 2.71% | 2.14% |
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
NBIX vs. ABT - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Abbott Laboratories. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. ABT - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
ABT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported a gross profit of 6.28B and revenue of 11.16B. Therefore, the gross margin over that period was 56.3%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
ABT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported an operating income of 1.84B and revenue of 11.16B, resulting in an operating margin of 16.5%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
ABT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported a net income of 1.08B and revenue of 11.16B, resulting in a net margin of 9.7%.
Frequently Asked Questions
NBIX and ABT have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NBIX has higher volatility (12.60%) compared to ABT (7.34%). In terms of maximum drawdown, NBIX dropped -97.21% vs ABT's -45.66%.
NBIX currently has the higher Sharpe Ratio (1.04 vs -1.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NBIX and ABT
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer